RecruitingPhase 1Phase 2NCT06546111
Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection
Sponsor
Sadat City University
Enrollment
46 participants
Start Date
Oct 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study intends to assess the possible effectiveness and safety of Diosmin and Hesperidin combination in patients with Helicobacter pylori Infection through evaluating its effect on stool antigen test and serum levels of inflammatory biomarkers as(TNF-A and MDA).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Confirmed H. pylori infection through stool antigen test.
- Patients did not receive prior eradication therapy.
- Male and female.
- Age of 18-75 years old.
- Good mental well-being to clearly understand the study's objectives, advantages and procedures.
Exclusion Criteria15
- Age less than 18 years.
- Patients with previous H. pylori eradication therapy.
- Patients with hypersensitivity/allergy to the study medications.
- Patients with history of using proton pump inhibitor, H2-blocker, antibiotics that affect H.
- pylori in the last month.
- Patients with history of using diosmin and/or hesperidin in the last month.
- Patients with history of gastric tumor or gastrointestinal (GI) surgery.
- Patients with concomitant severe disorders; cardiovascular, pulmonary, renal or hepatic, or active malignancy.
- Pregnancy or breastfeeding.
- History of drug misuse or recent alcohol consumption.
- Patients with gall bladder disorders.
- Patients on blood thinning agents (warfarin, clopidogril, aspirin, etc), anticonvulsants (carbamazepine and phenytoin), muscle relaxants (chlorzoxazone) and NSAID (diclofenac) in order to avoid potential pharmacodynamic and pharmacokinetic drug interactions with diosmin.
- Patients on anti-inflammatory drugs and antioxidant drugs.
- Patients with inflammatory conditions (ulcerative colitis, rheumatoid arthritis, etc.).
- Patients with conditions associated with oxidative stress (smoking, COPD, etc.).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPlacebo
Drug :placebo tab PO BID for 14 days.
DRUGDaflon
Daflon 500 mg tab PO BID for 14 days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06546111
Related Trials
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
NCT074394451 location
Tegoprazan-containing Sequential for H. Pylori
NCT063824931 location
Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
NCT075376342 locations
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
NCT053324441 location
Effect of PPIs on Stool DNA Test for H. Pylori
NCT075162621 location